ATARA Biotherapeutics (ATRA) Announces Proposed Common Share & Pre-Funded Warrants Offering

Go back to ATARA Biotherapeutics (ATRA) Announces Proposed Common Share & Pre-Funded Warrants Offering

ATARA Biotherapeutics (ATRA) Prices 12.63M Share Common Offering at $11.32/Sh

May 27, 2020 5:57 AM EDT

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) today announced the pricing of an underwritten public offering of 12,633,039 shares of its common stock at a price to the public of $11.32 per share and, to certain investors, pre-funded warrants to purchase 2,866,961 shares of its common stock at a purchase... More

ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN

May 26, 2020 7:05 AM EDT

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of additional safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive... More

ATARA Biotherapeutics (ATRA) call put ratio 7.3 calls to 1 put with focus on June 20 calls

May 22, 2020 2:24 PM EDT

ATARA Biotherapeutics (NASDAQ: ATRA) call put ratio 7.3 calls to 1 put with focus on June 20 calls

... More

UPDATE: ATARA Biotherapeutics (ATRA) Trades at High, Up 20%

May 22, 2020 2:13 PM EDT

(Updated - May 22, 2020 2:18 PM EDT)

ATARA Biotherapeutics (NASDAQ: ATRA) climbed 20% Friday afternoon. The company was set to present ATA188 data in MS at the EAN Congress today.

... More